Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck

Catimel, G.; Verweij, Jaap; Mattijssen, V.; Hanauske, Axel‐R.; Piccart, Martine; Wanders, J.; Franklin, H. R.; Bail, N Le; Clavel, M.; Kaye, Stanley B.

doi:10.1093/oxfordjournals.annonc.a058908

Cited by 221 publications

(99 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In three phase II studies (Table 1), single-agent docetaxel (100 mg m À2 ) administered on day 1 every 3 weeks produced response rates ranging from 21 to 42% (Catimel et al, 1994;Dreyfuss et al, 1996;Couteau et al, 1999). As expected, grade III -IV neutropenia was the principal toxicity in these studies.…”

Section: Potential Of Docetaxel In Scchnmentioning

confidence: 52%

“…Perhaps the most promising agents have been the taxanes. In particular, the taxane docetaxel has demonstrated significant single-agent activity in recurrent SCCHN (Catimel et al, 1994;Dreyfuss et al, 1996;Couteau et al, 1999). Docetaxel is similar to paclitaxel with respect to its general mechanism of action (tubulin stabilization and cell cycle arrest), and the two share a number of pharmacological characteristics (Colevas and Posner, 2001).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck

Posner

Lefèbvre

2003

Br J Cancer

View full text Add to dashboard Cite

Patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) are often treated with induction chemotherapy or chemoradiotherapy, but to date without major impact on survival. The combination of cisplatin -5-fluorouracil (5-FU) (PF) has been used as standard induction therapy; however, poor patient survival has stimulated investigation into new agents with potential activity in SCCHN. Docetaxel has significant single-agent activity in SCCHN and has been investigated in combination with PF regimens as induction therapy. The results of six phase II studies of docetaxel -PF regimens (TPF) as induction in locally advanced SCCHN patients are reviewed and reported. Consistently, high 2-year survival rates and overall response rates were demonstrated across the phase II trials in the range 42 -82 and 71 -100%, respectively. The toxicity profile seen with TPF-based regimens was acceptable. The primary toxicity was neutropenia, which together with gastrointestinal complaints accounted for the majority of adverse events. Given the encouraging phase II experience with TPF-based regimens, two large-scale phase III studies comparing TPF-based regimens with standard PF regimens are underway. The results have significant potential for validating the findings of the phase II studies, demonstrating improved survival and overall response of patients treated with docetaxel-based induction chemotherapy.

show abstract

Section: Potential Of Docetaxel In Scchnmentioning

confidence: 52%

mentioning

confidence: 99%

Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck

Posner

Lefèbvre

2003

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…A phase II clinical trial of docetaxel monotherapy for the treatment of advanced/recurrent ESCC reported a response rate of 20.4%. These findings indicate that docetaxel may be a useful chemotherapeutic agent for the treatment of ESCC (9)(10)(11)(12).…”

Section: Introductionmentioning

confidence: 76%

Radiation-sensitizing effect of low-concentration docetaxel on human esophageal squamous cell carcinoma cell lines

Tabuchi

Ozawa

Koyanagi

et al. 2011

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Esophageal squamous cell carcinoma (ESCC)is more sensitive to radiation and chemotherapy than other cancers of the digestive system, and combined modality therapy may represent a promising treatment method. The radiation-sensitizing effect of docetaxel on ESCC cell lines was investigated. A colony formation assay was performed in which ESCC cell lines (TE2, TE3) and A431 were exposed to docetaxel (from 1.0x10 -11 to 10 -7 M) for 3 h to determine the concentration of docetaxel that was not able to kill individual cells (i.e., the non-cytocidal concentration). Individual cell lines were then exposed to the non-cytocidal concentration of docetaxel prior to, during, and after irradiation to determine whether the timing of docetaxel administration affected cell survival. In addition, flow-cytometry was performed, and the cell cycle was examined prior to and after docetaxel exposure to assess the mechanism of docetaxel as a radiation sensitizer. Docetaxel exhibited a concentration-dependent cytocidal effect, with a different IC 50 for each cell type. Almost no cytocidal effect was observed at the following docetaxel concentrations: A431, ≤1.0x10 -10 M; TE-2 and TE-3, ≤1.0x10 -9 M. Concurrent treatment with docetaxel and radiation tended to decrease cell survival in all the cell lines compared with docetaxel or radiation alone. Cell survival was lowest when the cells were treated using X-ray irradiation after docetaxel exposure (p<0.05). Flow cytometry revealed that in all three cell lines, docetaxel exposure increased the G2/M cell fraction with a higher increase in the cell line that exhibited the highest radiosensitivity. This study demonstrated that the administration of docetaxel at a non-cytocidal concentration prior to radiotherapy produced a synergistic cell-killing effect in SCC cell lines.

show abstract

“…The utility of docetaxel for head and neck disease has been confirmed in the clinic. Docetaxel has demonstrated activity in the setting of advanced metastatic disease, [5][6][7] and is feasible in combination with concurrent daily radiotherapy. 8 -10 The current trial builds on these previous reports by using two complementary clinical strategies.…”

Section: Conclusion This Regimen Was Feasiblementioning

confidence: 99%

Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck

Schwartz

Montgomery

Yueh

et al. 2005

Cancer

View full text Add to dashboard Cite

BACKGROUNDThe current Phase I/II study assessed induction docetaxel/carboplatin given weekly for 4 weeks, followed by weekly docetaxel/carboplatin and concomitant boost radiotherapy (CB‐XRT) for locally advanced head and neck squamous cell carcinoma.METHODSTwenty patients with Stage III or IV (M0) disease of the oropharynx, supraglottic larynx, or hypopharynx were enrolled. Patients initially received docetaxel 20 mg/m2 and carboplatin area under the curve (AUC) 2 weekly × 4. Patients with stable (SD) or responding disease subsequently received dose‐escalated docetaxel (10–20 mg/m2 in sequential patient cohorts) and carboplatin AUC 1 weekly × 5 with CB‐XRT (1.8 gray [Gy] every day × 15 days, followed by 1.8/1.5 Gy twice per day × 13 days).RESULTSAll patients were evaluable, and 15 patients (5 patients with Stage III disease, 10 patients with Stage IV disease) completed all planned therapy. The target docetaxel dose level of 20 mg/m2 weekly with radiotherapy was achieved with no dose‐limiting toxicities. The most frequent maximum toxicities during chemoradiotherapy were Grade 3 mucositis, dysphagia, and/or pain. Primary site responses after induction included 4 patients with partial responses, 11 patients with SD, and 5 patients with disease progression. Fifteen patients (75%) continued to receive chemoradiotherapy, with 14 patients attaining a complete response (CR). Overall, a clinicopathologic neck CR after chemoradiotherapy was achieved in 9 of 10 patients. One patient had persistent primary disease and underwent salvage surgery, whereas another died of unrelated causes before neck assessment. Thirteen patients remain free of any disease event, with a median follow‐up of 15 months (range, 3–29 months).CONCLUSIONSThis regimen was feasible, safe, and particularly well tolerated. Early Phase II outcomes revealed promising activity in patients completing all treatment. Initial induction response results suggested that further investigation of this regimen with more aggressive induction therapy is warranted. Cancer 2005. © 2005 American Cancer Society.

show abstract

Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck

Abstract: Docetaxel is an active drug in patients with advanced squamous cell carcinoma of the head and neck.

Cited by 221 publications

References 12 publications

Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck

Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck

Radiation-sensitizing effect of low-concentration docetaxel on human esophageal squamous cell carcinoma cell lines

Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck

Contact Info

Product

Resources

About